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Background: The aim of this study was to determine the bacterial species recovered from 61 cats with lower
urinary tract infection (LUTI), and their susceptibility to cefovecin in vitro.
Results: The clinical signs and final clinical diagnosis for cats with confirmed LUTI were also reported. After physical
examination of the cats, urine samples including ≥5-6 leucocytes in microscopic evaluation were cultured using
bacteriological techniques. The isolates were identified by conventional microbiological methods and tested for
in vitro susceptibility using the Kirby-Bauer disc diffusion method recommended by the Clinical Laboratory Standards
Institute. Bacterial growth was observed in 16 of 61 urine samples. Antimicrobial susceptibility tests showed that 13 of
16 (81%) isolates were susceptible to cefovecin. The most frequently isolated bacterium from cats with signs of lower
urinary tract infection, was Escherichia coli.
Conclusion: Cefovecin was found to be effective in cats with LUTI. Because cefovecin is a new antimicrobial agent in
veterinary medicine, there are only few studies about urine culture of cats with LUTI. It is the first study on in vitro
activity of cefovecin against bacterial isolates from cats with lower urinary infections in Istanbul, Turkey.
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Lower urinary tract infections (LUTI) are rarely seen in
cats, dogs and human beings. Various lower urinary tract
disorders can predispose to opportunistic infections as a
complication of the underlying disease or its treatment,
while bacteria can be the initial cause [1].
Urine culture is the gold standard used to confirm the
diagnosis of urinary tract infection (UTI). The urine
sample used for this purpose should be obtained by
cystocentesis to avoid bacterial contamination from the
lower urogenital tract flora [2].
In urinary tract infections of cats and dogs, the most
commonly isolated bacterial species were reported as
Escherichia coli, Proteus spp., Staphylococcus spp. and* Correspondence: kayar@istanbul.edu.tr
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ous species varied considerably [3,4].
Cephalosporins belong to the beta-lactam group of anti-
biotics and they are originally derived by hydrolysis from
the natural compound of Cephalosporin C. This class is
bactericidal and acts by inhibiting the synthesis of the pep-
tidoglycan layer of the bacterial cell wall through binding
to the penicillin binding protein (PBP) [5].
Cefovecin sodium [Convenia®; Pfizer Animal Health; USA]
is a newly developed, semi-synthetic, extended-spectrum
injectable third-generation cephalosporin administered
at 8 mg/kg subcutaneously (SC) for the treatment of
UTI and skin and soft tissue infections in dogs and
cats and it has been approved for subcutaneous (SC)
injections in cats since 2006 in EU and 2008 in USA [4,6-9].
Third generation cephalosporins are generally less active
than members of the first or second generation formula-
tions against gram-positive organisms (e.g., Streptococcus
spp. or Staphylococcus spp.) [5]. Stegemann et al. [4]tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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against Gram-negative organisms isolated from dogs
and cats, including Escherichia coli, Pasteurella multocida,
Klebsiella spp. (including K. pneumonia), Enterobacter spp.
and anaerobic-growing pathogens Fusobacterium spp.,
Bacteriodes spp., Prevotella oralis. However it was not ef-
fective against most Pseudomonas aeruginosa isolates.
The aim of this study was to determine the bacterial
species recovered from cats with LUTI, and their sus-
ceptibility to cefovecin in vitro. The clinical signs and
final clinical diagnosis for cats with confirmed LUTI
were also reported.Table 1 Diseases/disorders determined in 61 cats with
lower urinary tract signs
Disorders Number of cats Culture-positive cats
Haemorrhagic cystitis 8 2
Polypoid cystitis 3 -




Urethral plaque 14 4Methods
Samples
In this study, 90 cats with one or more urinary clinical
signs such as stranguria, haematuria, pollakiuria, inappro-
priate urination, excessive licking of the genital area and
frequent and/or prolonged attempts to urinate were phys-
ically examined at the Department of Internal Medicine,
Faculty of Veterinary Medicine, Istanbul University and
their anamnesis was gathered. Complete Blood Count
(CBC), blood serum biochemistry (Serum glucose, blood
urea nitrogen (BUN), creatinine, alanine aminotransferase
(ALT), aspartate aminotransferase (AST)) and urine ana-
lyses were performed in all patients. Twenty-nine cats
were excluded from the study because antimicrobial treat-
ment had already commenced in private veterinary clinics
prior to our physical examination. Sixty-one cats with no
antimicrobial treatment and including ≥5-6 leucocytes in
urine microscopic examination were included in the study.
The examination focussed on the presence of pyuria (≥5
white blood cells/high magnification (40x objective; high-
power field, (hpf)) which were indicator of LUTI. The cats
in the sample group were from different breeds: mixed
(n:38), Persian (n:11), Siamese (n:5), Turkish Van (n:3),
Turkish Angora (n:4). Forty-one cats were male, 20 cats
were female. Five of the cats were one year old or younger,
38 between 2–7 years old and 18 were 8 years old or older.
Samples of 5 ml of urine were collected by ultrasound-
guided cystocentesis. Cats were restrained in lateral re-
cumbency, the caudal abdomen area was cleaned with
alcohol then the needle was inserted. Urine samples
for culture and antimicrobial susceptibility tests were
sent to the laboratory within 1 hour, stored in cooling
boxes.Bladder stones 3 1
Urethritis 2 -
Acute Renal Failure 8 3
Chronic Renal Failure 6 2
Diabetes Mellitus 2 1
Other diseases 9 2Medical imaging
Abdominal radiography and ultrasonography were also per-
formed to diagnose underlying urinary diseases/disorders
of the cats. Abdominal ultrasonography was performed
using a 3.75-MHz convex transducer (Schimadzu 350-A,
Shimadzu Corporation, Kyoto, Japan).Culture
The samples were sent for bacteriological examination
to the Laboratory of the Microbiology Department of
Istanbul University, Faculty of Veterinary Medicine. Urine
samples were inoculated onto nutrient agar supplemented
with 7% sheep blood (blood agar) and MacConkey agar
plates. While the MacConkey agar plates were incubated
aerobically, the blood agar plates were incubated under
aerobic and microaerobic conditions at 37°C for 7 days.
The colonies were examined macroscopically and then
microscopically using Gram staining. Biochemical identifi-
cation was performed by conventional methods and all
the isolates were confirmed with API systems (BioMérieux,
SA, Marcy I’Etolie, France) [10,11]. A bacterial count of
more than 103 cfu/ml was considered diagnostic of UTI
[9]. Cultures with no growth after 7 days were interpreted
as negative.Antimicrobial susceptibility tests
The antibiotic susceptibility tests were performed ac-
cording to the Kirby-Bauer method recommended by
the Clinical Laboratory Standards Institute (CLSI) to se-
lect the optimal antimicrobial agent for treatment [12].
The zone of inhibition around the disk (30 μg cefovecin)
was measured. The inhibition zone of ≥ 23 mm was con-
sidered as susceptible, while 20–22 mm as intermediate
and ≤ 19 mm as resistant [6,12].Statistical analyses
The results were analysed with the SPSS 13.0 programme.
The Chi-squared test was used for the comparisons of
gender groups and age groups with respect to bacter-
ial growth. Differences were considered significant at
p < 0.05.
Table 2 Number of leucocytes detected by urine
microscopic examination
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Clinical signs
The most common presenting clinical signs of bacterial
lower urinary tract infection in cats were pollakiuria (n = 41)
followed by stranguria and haematuria, respectively.
Clinical disorders associated with lower urinary tract signs
Disorders and the number of cats involved are given in
Table 1. Sixteen culture-positive cats were diagnosed
with the following conditions: urethral plaque (n:4),
feline idiopathic cystitis (n:1), haemorrhagic cystitis
(n:2), bladder stones (n:1), acute renal failure (n:3), chronic
renal failure (n:2), diabetes mellitus (n:1), other diseases
(n:2). The final diagnosis was reached following anamnesis,
physical examination, blood and urine analysis, medical
imaging and urine culture.
Complete Blood Count (CBC) and blood serum biochemistry
All the animals in the study were found to be within the
normal range of CBC parameters. At the same time,
leucocytosis was not observed in 16 culture-positive cats.
Biochemical blood serum values (Serum glucose, blood
urea nitrogen, creatinine, alanine aminotransferase, as-
partate aminotransferase) were determined for every pa-
tient. In our study, these parameters were found not to
be significant.
Medical imaging
Blood clot formation was seen in the urinary bladder in







Figure 1 Type and number of bacterial species isolated in cats.of the clots was variable (hypo- to hyper-) and the bladder
wall was thickened. Bladder stones were seen hyperechoic
and distal shadows were detected. The bladder wall was
also thickened in cats diagnosed with renal failure and cyst-
itis. No abnormal findings were seen in cats with urethritis.
The sonographic appearance of transitional cell carcinoma
was irregular, its shape was irregular and the echogenicity
seemed non-homogenous. The ultrasonographic findings
are compatible with our diagnosis.
Urine analysis microscopic evaluation
Leucocyte numbers detected by urine microscopic evalu-
ation are summarized in Table 2.
Bacterial growth was observed in 16 of 61 (26.2%) cats
urine samples with a leucocyte count ≥ 5–6 leucocytes
(Figure 1). All the isolates were pure cultures.
Bacterial growth and susceptibility testing
Bacterial growth was observed in 5 of 20 (25%) urine
samples of female cats and in 11 of 41 (26.8%) samples
of male cats (p > 0.05). Three in five cats (60%) with bac-
terial LUTI were 1 year old or younger, 9/38 (23.6%) 2–
7 years old and 4/18 (22.2%) 8 years old or older (p > 0.05).
In this study, no significant difference was found between
female and male cats with bacterial LUTI (p = 0.879).
The differences among age groups were also not sig-
nificant (p = 0.200).
Antimicrobial susceptibility tests results showed that
13 of 16 (81%) isolates were susceptible to cefovecin.
E. avium and S. epidermidis isolates were resistant and
Arcanobacterium renale isolate was intermediate.
Discussion and Conclusions
Incorrect therapy of urinary tract disease, overuse and
misuse of antimicrobials can have negative effects on pa-
tient health (e.g. failure to resolve infections), the alloca-
tion of resources (e.g. need for repeated or prolonged
treatment), and public health (e.g. antimicrobial resistance)
and may raise regulatory concerns (e.g. antimicrobial use)Escherichia coli (n = 4)
Coagulase negave
Staphylococcus spp. (n = 3)
Enterococcus faecalis (n = 2)
S. pseudintermedius (n = 2)
S. aureus (n = 1)
S. epidermidis (n = 1)
Arcanobacterium renale (n = 1)
Enterococcus avium (n = 1)
Enterobacter cloacea (n = 1)
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that of other cephalosporin antibiotics, which share low
toxicity and good activity against many Gram-positive and
Gram-negative aerobic bacteria [6].
Bacterial urinary tract infections (UTIs) in cats are
relatively rare [14]. Studies of cats with clinical signs of
lower urinary tract disease (dysuria, stranguria, polla-
kiuria) have consistently shown that the overall preva-
lence of positive bacterial urine cultures is <3% [2,15].
Some studies have reported much higher prevalence
rates (15–43%) in cats that have their urinary tract de-
fence mechanisms compromised by the effects of other
diseases and/or by the treatment [2]. In this study, bac-
terial growth was observed in 26.2% of cats’ urine sam-
ples with ≥ 5–6 leucocytes. Our findings confirm to a
large extent to the results reported by Weese et al. [15].
Bacteriuria is generally seen in older cats [16]. In our
study, the percentage of young cats (≤1 years old) was
highest. Most of the younger cats in our sample group
spent time both indoor and outdoor. They generally
hunted and usually drank water from flower bowls and
ponds. These risk factors and their close contact with
stray cats, may have contributed to the high prevalence
of urinary problems in this age group compared to in-
door and older cats.
Urine analyses were shown to be a useful indicator for
UTIs. The most commonly isolated bacteria of cats with
urinary tract infections were reported to be Escherichia coli,
Enterococcus spp., Staphylococcus spp. and Streptococcus
spp. [4,6,9]. Our results support these findings.
Proper and timely diagnosis is critical for the treat-
ment of lower urinary tract infections as well as for the
selection of appropriate antimicrobials and drugs. Cefo-
vecin has been specifically developed for the animal
practice as a long-acting third-generation cephalosporin
with duration of action of 14 days. Stegemann et al. [4]
reported that cefovecin exhibited a broad activity against
a range of Gram-negative pathogens and was not active
in vitro against P. aeruginosa. Wernick and Müntener
[5] have reported that cefovecin showed no bactericidal
activity against Enterococcus spp. but it is active against
Arcanobacterium renale. Our results (81% of isolates
susceptible to cefovecin) are in agreement with these
findings. However, E. avium isolate was found to be re-
sistant, and Arcanobacterium renale isolate to be of
intermediate susceptible to cefovecin. Stegemann et al.
[4] reported that cefovecin was not appreciably active
against Enterococcus spp., although in this study E. faecalis
isolates were found to be susceptible in vitro. While litera-
ture suggests good activity of cefovecin against coagulase-
negative staphylococci, in this study S. epidermidis isolate
was resistant to cefovecin [4,8].
It is known that antimicrobials are the cornerstone of
LUTI therapy. Despite the high cost of cefovecin inTurkey, its effectiveness and usefulness have been dis-
cussed in this study. Cefovecin is one of the antimicro-
bial agents that can be used in lower urinary tract
infections and it is easy to administer a single injection.
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